Today at #ESMO26 in Madrid, we shared new Phase 1 data on our investigational FRα-targeting antibody-drug conjugate in heavily pretreated patients with platinum-resistant ovarian cancer.

The results reinforce our confidence in the potential of this approach to help expand treatment options for patients with ovarian cancer.

Read the key data highlights here: https://ir.zymeworks.com/news-releases/news-release-details/zymeworks-presents-new-phase-1-data-folate-receptor-alpha-0

#OvarianCancer #ADC